Keywords

Aging, azithromycin, biomarker, COPD, exacerbation, mortality, quality of life, senescence, telomere

Disclosure

Don D Sin has received research funding from drug companies: AstraZeneca, Merck and Boehringer Ingelheim,

Keywords

Aging, azithromycin, biomarker, COPD, exacerbation, mortality, quality of life, senescence, telomere

Disclosure

Don D Sin has received research funding from drug companies: AstraZeneca, Merck and Boehringer Ingelheim, and has received honoraria for serving on COPD advisory committees of Boehringer Ingelheim, AstraZeneca and Sanofi-Aventis.

Acknowledgements

Medical writing assistance was provided by Katrina Mountfort of Touch Medical Media and was supported by Touch Medical Media.

Review Process

This is an expert interview and, as such, has not undergone the journal’s standard peer review process.

Authorship

The named author meets the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, takes responsibility for the integrity of the work as a whole, and has given final approval for the version to be published.

Open Access

This article is published under the Creative Commons Attribution Non-commercial License, which permits any non-commercial use, distribution, adaptation, and reproduction provided the original author and source are given appropriate credit. © The Author 2018.

Received

July 15, 2018

Published Online

September 17, 2018

Correspondence

Don D Sin, MD, FCCP, Centre for Heart Lung Innovation, St. Paul’s Hospital, 1081 Burrard St, Vancouver, BC, Canada, V6Z 1Y6. E: Don.Sin@hli.ubc.ca Twitter: @donsin4

Support

No funding was received in the publication of this article.